[1] Ash S, Stein J, Askenasy N,et al.Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation. Br J Cancer. 2010; 103:1597-1605.
[2] Koyama M, Hashimoto D, Aoyama K, et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood. 2009;113:2088-2095.
[3] Kronsteiner B,Peterbauer-Scherb A,Grillari-Voglauer R,et al. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol. 2011;267:30-38.
[4] 柯俊龙,许志恩,李华,等.较高温度下骨髓间充质干细胞的复苏率及复苏后分化[J].中国组织工程研究与临床康复,2010,14(27): 4975-4978.
[5] Reagan MR,Ghobrial IM.Multiple myeloma mesenchymal stem cells: characterization,origin,and tumor-promoting effects.Clin Cancer Res. 2012;18(2):342-349.
[6] 张之南,沈悌. 血液病诊断及疗效标准[M].3版.北京:科学出版社,2008.
[7] Shen Jianliang,Huang Youzhang, Xu Shixia. Effectiveness of human mesenchymal stem cells derived from bone marrow cryopreserved for 23-25 years.Cryobiology. 2012;64(3): 167-175.
[8] 赵智刚,唐晓琼,黎纬明,等.冻存前后骨髓间充质干细胞的生物学特性和支持造血的研究[J].中国实验血液学杂志,2006,14(2): 304-307.
[9] Zhao ZG, Li WM Chen ZC,et al. Hematopoiesis capacity, immunomodulatory effect and ex vivo expansion potential of mesenchymal stem cells are not impaired by cryopreservation. Cancer Invest. 2008;26(4):391-400.
[10] Meirelles Lda S, Fontes AM, Covas DT,et al.Mechanisms involved in the therapeutic properties of mesenchymal sem cells.Cytokine Growth Factor Rev.2009;20(5-6):419-427.
[11] Gonda K, Shigeura T, Sato T, et al. Preserved proliferative capacity and multipotency of human adipose-derived stem cells after long-term cryopreservation. Plast Reconstr Surg. 2008;121(2):401-410.
[12] Mamidi MK, Nathan KG, Singh G, et al .Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation.Cell Biochem.2012; 113(10): 3153-3164.
[13] Yang H, Robinson SN, Nieto Y, et al.Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res.2011;71(14): 5040-5049.
[14] Corre J, Mahtouk K, Attal M, et al.Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007; 21:1079-1088.
[15] Martínez-Jaramillo G,Vela-Ojeda J,Flores-Guzmán P,et al. In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma.Leukemia. 2011;35(2):250-255.
[16] Görgün G,Calabrese E,Soydan E,et al.Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116(17): 3227-3237.
[17] Feng Y, Wen J, Mike P, et al. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells.2010;19(9): 1289-1296.
[18] Gahrton Gösta.Progress in allogeneic transplantation for multiple myelomaEur. Eur J Haematology. 2010;85(4): 279-289.
[19] Bensinger W.Role of autologous and allogeneic stem cell transplantation in myeloma.Leukemia.2009;23(3):442-448.
[20] Capitini CM,Herby S,Milliron M,et al.Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD- associated immunosuppression and enhances a tumor-specific GVT effect.Blood.2009;113:5002-5009.
[21] Auletta Jeffery J, Deans Robert J, Bartholomew Amelia M.Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.Blood. 2012;119(8): 1801-1809.
[22] Kumar A Loughran T, Alsina M,et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies.Lancet Oncology.2003;4(5):293-304.
[23] Garderet L,Mazurier C,Chapel A,et al.Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leukemia Lymphoma. 2007;48(10):2032-2041.
[24] Arnulf B,Lecourt S,Soulier J,et al.Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.Leukemia. 2007; 21(1):158-163.
[25] Jiang Y,Jahagirdar BN,Reinhardt RL,et al.Pluripoteney of mesenehymal stem cell derived from adult nlarrow.Nature. 2002; 418(6893):41-49.
[26] Koc ON,Lazarus HM.Mesenchymal stem cels:heading into the clinic.Bone Marrow Transplant.2001;27:235-239.
[27] Lee K,Majumdav Mk,Buyaner D,et al.Human mesenchymal stem cells maintain transgene expression during expansion and diferentiation.Mo1ther.2001;3:857-864.
[28] Lazarus H,Curtin P,Devine S.Role of mesenchymal stem cells in allogeneic transplantation:early phase I clinical results. Blood.2000;392:1691-1698.
[29] Zhao Z,Tang X,YouY,et aL Assessmentt of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia.Leukemia Res.2006;30(8):993-1003.
[30] Zhang ZY, Teoh SH, Hui JH,et al.The potential of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering application.Biomaterials.2012;33(9):2656-2672.
[31] Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells.Immunology.2012;136(2):133-138.
[32] Hao i,Sun H,Wang J,et al.Mesenchymal stromal cells for cell therapy:besides supporting hematopoiesis.Hematol. 2012; 95(1):34-46.
[33] Martino A, Buda G, Maggini V, et al. Could age modify the effect of genetic variants in IL6 and TNF-α genes in multiple myeloma?Leuk Res.2012; 36(5):594-597.
[34] Brown CO,Salem K,Wagner BA,et al.Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. The Biochemi J.2012;444(3): 515-527.
[35] Ohgiya D, Matsushita H, Onizuka M, et al. Association of Promyelocytic Leukemia Protein with Expression of IL-6 and Resistance to Treatment in Multiple Myeloma.Acta Haematol. 2012;128(4):213-222. |